Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy — Miwa Kawanaka (2014) | RDL Network
Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy
Article 2014 en
Authors
MK
Miwa Kawanaka
KN
Ken Nishino
JN
Jun Nakamura
Abstract
1 min read
Hepatocarcinogenesis was observed in patients with high HBsAg levels, despite the negative conversion of HBV DNA as a result of long-term NA therapy. Therefore, to suppress hepatocarcinogenesis, it is important to control not only HBV DNA levels but also HBsAg levels.
Stephen L. Chan, Andrew X. Zhu, Richard S. Finn, Julien Edeline, Sadahisa Ogasawara, Jennifer J. Knox, Bruno Daniele, Baek‐Yeol Ryoo, Philippe Merle, Mohamed Bouattour, Ho-Yeong Lim, Yee Chao, Thomas Yau, Barbara Haber, Usha Malhotra, Chih‐Chin Liu, Masatoshi Kudo, Ann‐Lii Cheng
Soo Ki Kim, Soo Ryang Kim, Susumu Imoto, Madoka Tohyama, Yumi Otono, Tomoko Tamura, Ke Ih Kim, Mana Kobayashi, Aya Ohtani, Kayo Sugimoto, Aya Mizuguchi, Yukiko Hiramatsu, Masatoshi Kudo
Silvia Franceschi, Maurizio Montella, Jerry Polesel, Carlo La Vecchia, Anna Crispo, Luigino Dal Maso, Pietro Casarin, Francesco Izzo, Luigi Tommasi, Isabelle Chemin, Christian Trépo, M Crovatto, Renato Talamini
Discussion(0)
No comments yet. Be the first to comment.